Core Insights - The Q1 2025 earnings cycle is heavily focused on guidance, influenced by recent economic uncertainties and tariff announcements [1][9] - Several companies, including Centene, Boston Scientific, and Celestica, have raised their guidance, indicating positive performance [2][17] Centene (CNC) - Centene reported an adjusted EPS of $2.90 and sales of $46.6 billion, exceeding consensus estimates with a year-over-year earnings growth of 28% [3] - The company raised its 2025 premium and service revenues guidance by $6.0 billion, reflecting a 17% year-over-year improvement [3][6] - Analysts now expect Centene to post $172.8 billion in revenues for the current fiscal year, with a favorable Zacks Rank 2 (Buy) [6] Boston Scientific (BSX) - Boston Scientific surpassed both top and bottom line expectations, achieving a 12% EPS beat and sales 2.3% above expectations [8] - The company now anticipates FY25 sales growth between 15% and 17%, with current year sales expectations adjusted to $19.4 billion, a 10% increase from the previous year [10] Celestica (CLS) - Celestica exceeded Zacks Consensus EPS estimates by 8% and reported sales nearly 4% ahead of expectations, with a year-over-year sales growth of 20% [12] - The company raised its full-year 2025 revenue outlook to $10.85 billion from $10.7 billion, expecting non-GAAP adjusted EPS of $5.00, up from $4.75 [13] - Strong demand for solutions amid the AI trend and a shift to higher-margin products contributed to Celestica's stellar performance [13]

Boston Scientific (BSX) has been gaining from new product launches and accretive acquisitions. International expansion remains a key growth driver. The stock carries a Zacks Rank #2 (Buy).Factors Driving BSX SharesBoston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In Europe, the Middle East and Africa (EMEA), Boston Scientific is successfully expanding its base banking on its diverse portfolio, new launches and commercial executi ...

Core Viewpoint - Growth investors are increasingly focused on stocks with above-average financial growth, and Boston Scientific (BSX) is highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10] Earnings Growth - Boston Scientific has a historical EPS growth rate of 17.6%, with projected EPS growth of 15.8% for the current year, surpassing the industry average of 12.5% [4] Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 26.5%, significantly higher than the industry average of -8.8% [5] - Over the past 3-5 years, Boston Scientific's annualized cash flow growth rate has been 9.9%, compared to the industry average of 7.9% [6] Earnings Estimate Revisions - There have been upward revisions in current-year earnings estimates for Boston Scientific, with the Zacks Consensus Estimate increasing by 2.2% over the past month [8]

Boston Scientific (BSX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changin ...

Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Rick Wise - Stifel David Roman - Goldman Sachs Travis Steed - Bank of America ...

Boston Scientific Corporation (BSX) posted first-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 33.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 11.9% and also exceeded the company’s adjusted earnings per share guidance range of 66-68 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restru ...

For the quarter ended March 2025, Boston Scientific (BSX) reported revenue of $4.66 billion, up 20.9% over the same period last year. EPS came in at $0.75, compared to $0.56 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.56 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +11.94%, with the consensus EPS estimate being $0.67.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

Core Viewpoint - Boston Scientific Corporation announces the retirement of Dan Brennan, the executive vice president and chief financial officer, after nearly 30 years with the company, effective at the end of June 2025, with a transition period as a senior advisor until early October 2025 [1][2] Company Leadership Transition - Jon Monson, currently senior vice president of Investor Relations, will succeed Dan Brennan as executive vice president and CFO, effective June 30, 2025, reporting to CEO Mike Mahoney [2][3] - Brennan and Monson will collaborate closely to ensure a smooth transition, with Monson taking on responsibilities including global controllership, corporate finance, and corporate business development [2][3] Dan Brennan's Contributions - Dan Brennan has been recognized for his exceptional leadership and contributions to Boston Scientific, particularly in transforming the company's financial performance and developing talent within the financial organization [2][3] - Under Brennan's leadership since 2014, the company has overseen numerous strategic investment opportunities [2] Jon Monson's Background - Jon Monson has over 25 years of experience with Boston Scientific, having held various roles in finance, including global controller and chief accounting officer [3] - He is a certified public accountant with a Bachelor of Arts degree in economics and accounting from the College of the Holy Cross [3] Company Overview - Boston Scientific is a global leader in medical technology, providing innovative solutions to improve patient health and reduce healthcare costs [4] - The company has been advancing science for life for over 45 years, offering a wide range of devices and therapies for various medical conditions [4]

Financial Performance - Boston Scientific reported net sales of $4.663 billion for Q1 2025, a 20.9% increase on a reported basis, 22.2% on an operational basis, and 18.2% on an organic basis compared to the prior year[1][3]. - GAAP net income attributable to common stockholders was $674 million, or $0.45 per share, compared to $495 million, or $0.33 per share a year ago; adjusted EPS was $0.75, up from $0.56[1][3]. - Net sales for Q1 2025 reached $4,663 million, a 21% increase from $3,856 million in Q1 2024[21]. - Gross profit for Q1 2025 was $3,210 million, up from $2,648 million in Q1 2024, reflecting a gross margin improvement[21]. - Operating income increased to $921 million in Q1 2025, compared to $675 million in Q1 2024, representing a 36% growth[21]. - Net income attributable to Boston Scientific common stockholders for Q1 2025 was $674 million, a 36% increase from $495 million in Q1 2024[21]. - Basic net income per share for Q1 2025 was $0.46, up from $0.34 in Q1 2024, indicating a 35% increase[21]. - Adjusted net income for Q1 2025 was $1,121 million, compared to $832 million in Q1 2024, reflecting a significant increase[23]. Sales Growth - The Cardiovascular segment achieved a reported sales growth of 26.2%, while MedSurg grew by 11.7% compared to the prior year[3]. - U.S. sales increased by 31.1% to $2.96 billion, while EMEA and APAC regions saw growth of 5.5% and 8.2%, respectively[9]. - Full year 2025 net sales growth is estimated to be approximately 15% to 17% on a reported basis and 12% to 14% on an organic basis[11]. - For Q2 2025, the company expects net sales growth in the range of 17.5% to 19.5% on a reported basis and 13% to 15% on an organic basis[12]. - The company expects Q2 2025 net sales growth to be between 17.5% and 19.5%, with full-year growth estimated at 15.0% to 17.0%[27]. - Organic growth for Q2 2025 is projected to be between 13.0% and 15.0%, and for the full year, it is expected to be between 12.0% and 14.0%[27]. Research and Development - The company plans to continue investing in research and development, with R&D expenses increasing to $443 million in Q1 2025 from $366 million in Q1 2024[21]. Acquisitions and Clinical Trials - Boston Scientific completed the acquisition of Bolt Medical, Inc., and announced an agreement to acquire SoniVie Ltd., focusing on innovative medical technologies[7]. - The company commenced enrollment in the ELEVATE-PF clinical trial for the FARAFLEX™ Mapping and Pulsed Field Ablation Catheter targeting persistent atrial fibrillation[7]. Product Performance - The FARAPULSE™ PFA System demonstrated superior effectiveness in treating symptomatic paroxysmal atrial fibrillation compared to Medtronic's Arctic Front Advance™ catheter[7]. Operational Challenges - Boston Scientific is focusing on operational growth while managing the impact of acquisitions and divestitures, which is expected to affect growth rates negatively by approximately 4.5% in Q2 2025[27].

MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, ...